Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of Synaptic Density in Progressive MS using [F-18]SDM-8
NCT04634994Phase 1Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 18F-SynVesT-1 in multiple sclerosis (MS), sponsored by Brigham and Women's Hospital. Primary endpoint: PET measurements of synaptic density. Started May 2025; status: recruiting.
02
Drugs
18F-SynVesT-1
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04634994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634994.